Mo1837 – Effect of Upadacitinib on Extra-Intestinal Manifestations in Patients with Moderate to Severe Crohn’s Disease: Data from the Celest Study
Laurent Peyrin‐Biroulet(Délégation Centre-Est), Kristina Kligys(AbbVie (United States)), Qian Zhou(Nanjing Foreign Language School), Fabio Cataldi(Pfizer (United States)), Silvio Danese(IRCCS Ospedale San Raffaele), Édouard Louis(Centre Hospitalier Universitaire de Liège), Wan‐Ju Lee, Peter Higgins(Michigan Medicine), Marla C. Dubinsky(Icahn School of Medicine at Mount Sinai)
Cited by 2
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k